Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thrombolysis in Myocardial Infarction trials

Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E, for the TlMl Study Group. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003 42 7-16. [Pg.31]

Antman EM, Giugliano RR Gibson MC, etal., forthe TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis result of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999 99 2720. [Pg.56]

Antman EM, McCabe CH, Gurfinkel ER et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) I I B trial. Circulation 1999 100 1593-1601. [Pg.84]

Cannon CR McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction results of the thrombolysis in myocardial infarction (TIMI) 5 trial, J Am Coll Cardiol 1994 23 993-1003. [Pg.106]

Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, phase 11, pilot and clinical trial. Circulation 1991 83(2) 448-59. [Pg.3407]

Data regarding the acute benefit of /3-blockers in MI in the reperfusion era is derived mainly from the Thrombolysis in Myocardial Infarction (TIMI) II trial. In this trial, patients with ST-segment-elevation ACS were randomized to either IV metoprolol to be given as soon as possible following fibrinolytic administration followed by oral metoprolol or oral metoprolol deferred until day 6. Early administration of metoprolol was associated with a significant decrease in recurrent ischemia and early reinfarction. Patients receiving fibrinolytic therapy within 2 hours of symptom onset demonstrated the greatest benefit from early metoprolol administration. Based on the results of these trials, early administration of /8-blockers (to patients without contraindications) within the first 24 hours of hospital admission is a standard of quality patient care (see Table 16-3). [Pg.306]

Antman EM, McCabe CH, Enrique P, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation 1999 100(15) 1593-601. [Pg.38]

Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998 98(25) 2805-14. [Pg.42]

Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year resultsofthe Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Ant Coll Cardiol 1993 22(7) 1763-72. [Pg.43]

TlMl Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985 312 932-936. [Pg.21]

Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook PA, Maikis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel, BE, Willerson J, Williams DO, Zaret BL, Braunward E. Thrombolysis in myocardial infarction (TIMI) Trial, Phase I a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987 76 142-154. [Pg.59]

The TTMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TMI) Phase II Trial. N Engl J Med 1989 320 618-627. [Pg.61]

Results from the Thrombolysis in Myocardial Infarction (TIMI) I study confirmed that prompt myocardial reperfusion decreased mortality (1). Results of several large-scale trials before and after TIMI I were consistent in establishing that treatment with intravenously administered thrombolytic agents to recanalize infarct-related arteries decreased mortality in patients with ST elevation myocardial infarction (STEMI) (2,3). However, despite the obvious benefits of thrombolysis, 30-day mortality in the GISSI-2 and ISIS-3 trials was as high as 8-10% (4,5). Because early restoration of myocardial blood flow was shown to... [Pg.119]

Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TlMl) trial. Am J Cardiol 1988 62 179-185. [Pg.126]

Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circnlation. 1999 99 2720-2732. [Pg.172]

See other pages where Thrombolysis in Myocardial Infarction trials is mentioned: [Pg.519]    [Pg.519]    [Pg.89]    [Pg.97]    [Pg.447]    [Pg.456]    [Pg.21]    [Pg.22]    [Pg.29]    [Pg.30]    [Pg.41]    [Pg.60]    [Pg.38]    [Pg.133]    [Pg.171]    [Pg.184]   
See also in sourсe #XX -- [ Pg.3 , Pg.119 , Pg.135 ]



SEARCH



In trial

Infarct

Infarct, myocardial

Infarction

Myocardial infarction

Thrombolysis in myocardial infarction

© 2024 chempedia.info